ACO Annual Meeting at CAHR 2014

See the agenda (PDF)

Download the poster (PDF)

Read the executive summary (PDF)

The Canadian HIV Vaccine Initiative (CHVI) Research & Development Alliance Coordinating Office (ACO) Annual Meeting was held in tandem with the 23rd Annual Canadian Conference on HIV/AIDS Research (CAHR 2014).

More than 60 people attended the event, which focussed on developing innovative solutions for identified barriers to HIV vaccine development. Some of the key points raised during the meeting included:

  • Current and future prevention strategies against HIV infections will influence the design and implementation of future HIV vaccine clinical trials.
  • Canada has unique networks and expertise for clinical trial capacity and basic research.
  • Regulatory harmonization/convergence and capacity building are essential for future clinical trials in developing countries.
  • Building local and regional regulatory capacity is important for HIV vaccine clinical trials in Africa.
  • International partnerships can facilitate improvements in regulation of diagnostic products and vaccines.
  • Innovative manufacturing technologies offer many advantages and may have relevance to HIV vaccines.
  • Collaboration and partnerships are key for HIV vaccine development